The global cluster headaches market is predicted to grow from USD 478.3 million by 2028 from USD 384.7 million in 2023, growing at a CAGR of 4.45% from 2023 to 2028.
Cluster headaches are distinguished by severe, acute pain usually concentrated around one eye. They are one of the extreme headaches affecting many people globally. They occur in cyclical patterns or cluster periods. Cluster periods, which range from weeks to months, are frequently followed by remission periods in which the headaches disappear. During remission, there are no headaches for months or even years. The worldwide cluster headache market comprises therapeutic strategies and pharmaceuticals for managing and treating cluster headaches, a severe primary headache condition.
Impact of COVID-19 on the global cluster headache market:
The pandemic crisis has steady impact on the Cluster headache market. The global pandemic crisis has negatively impacted the development, production, and supply of pharmaceutical products and affected the growth of the treatment and medication used in the treatment of cluster headache disease. Due to social isolation and strict restriction many clinical trials and research studies related to the development of new treatment options for the evaluation of existing therapies for cluster headaches had disrupted. The disruption in the global supply chains led to potential shortages and delays in the availability of medication and treatment used for cluster headaches. During the pandemic, many people were taking different medicine for diseases without consulting the doctor, hence the rising consumption of such drugs are associated with many side effects including cluster headache this factor led to boosting the market growth during the pandemic.
MARKET DRIVERS:
One of the major key factors propelling the growth of the market is the rising prevalence of cluster cases in adults. Cluster headache affects nearly 1 in 1000 people globally, as more adults are diagnosed with cluster headache, hence there is an emerging demand for accurate diagnosis and effective treatment option, which drives the need for specialized healthcare services, and diagnostic tools contributing to the expansion of the cluster headache market. The rising prevalence of cluster cases in adults led to the development of innovative drugs and medical devices especially targeting cluster headaches, this led to the introduction of new medication, and delivery methods expanding the product offering within the market and helping in expanding the growth of the market.
The second major factor fueling the growth of the market is the emerging demand for steroidal drugs for the management of cluster headaches. Steroidal drugs are more effective in reducing the frequency of cluster headache attacks for some patients, this efficacy can drive the demand for these drugs. More interest in steroidal drugs for cluster headache management can lead to increased research and clinical trials to understand their effectiveness further fueling the growth of the market.
The third major factor favoring the growth of the market is the availability of improved healthcare infrastructure. The improved healthcare infrastructure provides better access to specialized medical professionals and diagnostic tools, this enables more accurate and timely diagnosis of cluster headaches, leading to appropriate and effective treatment plans. The well-developed healthcare infrastructure allows the availability of advanced treatment options including medication and surgical intervention, also the improved healthcare infrastructure facilitates the development and testing of new improvements and clinical trials boosting the growth of the market.
The other key factor propelling the growth of the global cluster headache market include the rising unmet healthcare needs, availability of improved healthcare infrastructure, rising prevalence of cluster cases in adults, and rising demand for steroidal drugs for the management of cluster headache, globally rising geriatric population, development of novel therapeutics for the treatment of cluster headache majorly favoring the growth of the market.
MARKET RESTRAINTS:
There are many factors rapidly driving the growth of the cluster headache market but there are some factors that negatively hamper the overall growth of the market. The major obstacle hindering the growth of the market is the lack of awareness and unfavorable healthcare policies have detrimental effects also the lengthy drug approval process and strict regulatory conditions hampering the growth of the market. The lack of awareness in public and healthcare professional lead to delayed diagnosis, and inadequate treatment. The stringent regulatory conditions can significantly impact patient access to diagnosis, treatment, and care, lack of insurance coverage for specialized treatment and therapies further limits the growth of the market. The regulatory approval process for developing new drugs can be time-consuming and resource-intensive, hence delays in the drug approval process can limit the availability of new and potentially more effective treatments for cluster headaches further hampering the growth of the market. Insufficient funding for research and development of cluster headache treatment can slow down the progress of developing novel therapies and innovative treatment approaches this factor further limits the growth of the market.
REPORT COVERAGE:
REPORT METRIC |
DETAILS |
Market Size Available |
2022 to 2028 |
Base Year |
2022 |
Forecast Period |
2023 to 2028 |
Segments Covered |
By Type, Drug Class, Distribution Channel and Region |
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
This research report on the global cluster headache market has been segmented and sub-segmented based on the type, drug class, distribution channel and region.
Global Cluster Headache Market – By Type:
Based on type, the chronic segment held the leading market share of 43.7% in the global cluster headache market. The rising awareness among population about the cluster headache and their chronic nature lead to more accurate and timely diagnosis, boosting the demand for appropriate treatment. The rising prevalence of chronic cluster headaches is on the rise, it can contribute to emerging the demand for treatment targeting this segment and favoring the market growth.
The episodic segment is also anticipated to hold a substantial market share in the global market. Episodic cluster headache occurs seasonally, this lead to increased awareness and treatment among patients. The factor such as ongoing research and development of fast-acting and acute treatments such as nasal spray, and inhalable medication leading to boosting the growth of the segment and propelling the growth of the market
Global Cluster Headache Market – By Drug Type:
Fast-acting Drugs
Long-term Drugs
Short-term Drugs
Based on drug type, the long-term drug segment holds the major share in the global cluster headache market. Long-term drug treatment demonstrates high efficacy in preventing and also reducing the frequency of cluster headaches. Cluster headaches often have a chronic and recurrent nature, long term drug treatment has a chronic and episodic nature, hence these drugs are useful to provide sustained relief and help the patient to manage their condition over an extended period. These all factors drive the growth of this segment and boost the market growth.
Fast acting drugs segment is also expected to hold a considerable share and show lucrative growth in the market. Cluster headache causes intense pain, burning sensation around the eyes, the patient requires rapid and effective relief to manage the sudden attack, also fast-acting drugs can quickly alleviate symptoms, this drugs can be self-administrated and align with patient preference, this factor boosting the growth of this segment and favoring the market growth.
Cluster Headache Market- Based on Route of Administration
Based on the route of administration, the oral segment accounted for 42.7% market share in 2022 and is projected to continue to dominate the market during the forecasted period. Oral medication is a convenient option for the patient which do not need specialized medical equipment, also this is an easy route of drug consumption, oral medication offers more flexibility in dosage adjustment, and the rising development of novel oral formulations allows more effective and targeted drug delivery, which can enhance treatment outcome and patient satisfaction, hence this all factor fueling the growth of this segment and boosting the growth of the market.
The topical segment also witnesses to register at a higher rate and earn more market revenue during the forecast period. Topical medication allows localized and targeted drug delivery to the specific area where the pain is experienced such as the forehead, this targeted approach provide rapid relief directly to the affected site, also they have a fast onset of action, providing quick relief and enhanced patient satisfaction and compliance hence as more benefits associated with this segment help in favoring the market growth.
Global Cluster Headache Market – By Distribution Channels:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Based on distribution channels, retail pharmacies accounted for the leading market share in 2022 and are anticipated to continue to dominate the market during the forecast period. Factor such as the rising preference of the people towards retail pharmacies favoring the growth of this segment, as retail pharmacies provide detailed guidance regarding medication and usage during the treatment period, hence this segment grows and fuels the market growth during the forecasted period.
The online pharmacies segment is anticipated to hold the highest market share and show lucrative growth in upcoming years. In recent years, due to the global pandemic crisis, people rapidly adopt digital health services such as telehealth and telemedicine because of their ease of convenience and time-saving ability, also pandemic crisis help to boost the growth of online pharmacies due to lockdowns and mandatory restrictions conditions hence this factor boosted the growth of this segment and expected to favors the market growth in the upcoming years.
Global Cluster Headache Market – By Region
North America is the leading region in the global cluster headache market. This region held the largest market revenue of 52.3% in 2022. The driver driving the growth of the market include the rising prevalence of cluster headache cases, the emerging prevalence of advanced healthcare infrastructure, and the rising number of key players offering novel therapeutics are anticipated to fuel the market growth.
The Asia-Pacific region is expected to show lucrative growth in this region and is anticipated to dominate the market at the fastest CAGR during the projected period. The rising number of headache disorders, rising awareness, and campaign, the rising investment in the development of effective drugs for treating cluster headaches are anticipated to favor the market growth during the projected period. In India, around 490 million suffer from headache disorders such as migraine, the rising prevalence of the headache disorder due to sedentary lifestyle habits such as consumption of alcohol and cigarette smokers, mental stress driving the growth of the market. In 2022, a report stated an 11.2% rise in the number of the smoker was noted, this rising chance of cluster headache prevalence boost the growth of the market, furthermore, many countries in this region such as Australia organize awareness program to educate people about cluster headache and available treatment option propels the market growth in APAC region.
Europe region is anticipated to grow at the fastest CAGR and hold a substantial market share during the projected period. The major factor boosting the growth of the market in this region include the growing infrastructure of industries, rising spending for headache disorders as well as the established presence of prominent key players, also the rising contract manufacturing organization within the region provides an opportunity for the growth of the market in this region.
Latin America and Middle East and Africa region anticipated to show lucrative growth and grow at a healthy CAGR in the global cluster headache market.
KEY MARKET PLAYERS:
The prominent key player in the global cluster headache market are Zosano Pharma, Eli Lilly and Company, Lundbeck Seattle BioPharmaceutical, Winston Laboratories, GlaxoSmithKline plc., ElectroCore Medical LLC, Autonomic Technologies, Inc., AstraZeneca plc., Allergan plc., Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sanofi, and AbbVie Inc.
RECENT HAPPENINGS IN THE MARKET:
Frequently Asked Questions
Some challenges in the cluster headache market include the limited understanding of the underlying mechanisms of the condition, delays in diagnosis, and the availability of effective treatments. Additionally, the high cost of certain medications and the need for improved access to specialized healthcare providers pose challenges to optimal patient care.
While cluster headaches can affect people of all ages, genders, and ethnicities, studies have shown that men are more commonly affected. Understanding the demographic factors can help in tailoring awareness campaigns and targeted treatment strategies.
Technological advancements, such as wearable devices for monitoring and tracking headaches, telemedicine platforms for remote consultations, and digital health solutions for personalized management, are shaping the cluster headache market and enhancing patient care.
The cluster headache market is populated by several pharmaceutical companies, medical device manufacturers, and research organizations. Some prominent players in this market include Eli Lilly and Company, Novartis AG, Teva Pharmaceutical Industries Ltd., ElectroCore, Inc., Allergan plc, Amgen Inc., GlaxoSmithKline plc, Pfizer Inc., Autonomic Technologies, Inc. and Lundbeck A/S.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region